|
ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). |
|
|
Honoraria - Abbvie; Beigene; Janssen-Cilag; Novartis; Pharmacyclics |
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche |
Research Funding - Abbvie (Inst); Janssen-Cilag (Inst) |
|
|
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Janssen; Merck; Novartis; Roche |
Consulting or Advisory Role - Abbvie; AstraZeneca; Gilead Sciences; Janssen; Merck; Novartis; Roche |
Research Funding - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Epizyme (Inst); Janssen (Inst); Merck (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - CSL Behring |
|
Travel, Accommodations, Expenses - Abbvie |
|
|
Research Funding - Acerta Pharma; BeiGene; GlycoMimetics |
Travel, Accommodations, Expenses - GlycoMimetics |
|
|
Honoraria - Celgene; Janssen |
Consulting or Advisory Role - Janssen |
Travel, Accommodations, Expenses - Janssen |
|
|
Honoraria - Abbvie; Celgene; Janssen-Cilag; Novartis; Roche |
Consulting or Advisory Role - Abbvie; Astellas Pharma; Celgene; Janssen-Cilag; Novartis; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Roche |
Research Funding - Gilead Sciences; Roche |
|
|
Honoraria - Abbvie; AstraZeneca; Janssen |
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen |
|
|
Consulting or Advisory Role - Janssen; Pharmacyclics; Roche/Genentech; Vical |
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Juno Therapeutics; Pharmacyclics |
Speakers' Bureau - Pharmacyclics/Janssen; Seagen |
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Juno Therapeutics |
|
|
Honoraria - BeiGene; Celltrion; Janssen; Roche |
Consulting or Advisory Role - BeiGene; Celltrion; Janssen; Roche |
Speakers' Bureau - BeiGene; Celltrion; Janssen; Roche |
Research Funding - BeiGene; Janssen; Roche |
|
|
Honoraria - Abbvie; Amgen; AstraZeneca; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen; Roche |
Speakers' Bureau - Abbvie; Janssen |
Travel, Accommodations, Expenses - Abbvie; Janssen; Roche |
|
|
|
Stock and Other Ownership Interests - BeiGene; Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
|
Stock and Other Ownership Interests - Amgen; BeiGene |
Travel, Accommodations, Expenses - BeiGene |
|
|
|
Stock and Other Ownership Interests - BeiGene |
Travel, Accommodations, Expenses - BeiGene |
|
|
|
|
Stock and Other Ownership Interests - BeiGene |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |